#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Extranodal marginal zone B-cell lymphoma (MALT type) B-cell lymphoma Epilepsy Essential thrombocythaemia Bladder cancer Ewing's sarcoma Palmoplantar pustulosis Cerebral arteriovenous malformation haemorrhagic Leiomyosarcoma Hypersensitivity pneumonitis Malignant melanoma Acquired haemophilia Neoplasm Mucous membrane pemphigoid Sjogren's syndrome More trials…

    Learn about Rare Diseases

    Hereditary ataxia – Basic Information Sarcoma Mitochondrial myopathy – Life with Disease Synovial sarcoma recurrent Pulmonary sarcoidosis – Basic Information Synovial sarcoma – Treatment Kearns-Sayre syndrome Propionic acidaemia Skin angiosarcoma Isodicentric chromosome 15 syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Esmolol Hydrochloride Ephedrine Hydrochloride Sufentanil Taminadenant GS-4321 Izaflortaucipir (18F) Ethanol (96 Per Cent) Rigosertib Sodium Doxribtimine Mianserin Hydrochloride Dalteparin Sodium Acetylsalicylic Acid Ph. Eur. Dazukibart Adezunap Imipenem TRIMIPRAMINE MALEATE SURVODUTIDE Pantoprazole Gskvx000000017033 Levamisole Hydrochloride More therapies…

    Learn about Your Condition

    Transplantation complication Torticollis Overweight Arrhythmia supraventricular Neuroendocrine tumour Duchenne muscular dystrophy Endometrial adenocarcinoma Heart transplant Pelvic venous thrombosis Coagulopathy Pneumonia bacterial Blood iron increased Leiomyosarcoma Arterial tortuosity syndrome Adrenocortical carcinoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • A Study of Cagrilintide and Semaglutide for Weight Loss in People with Type 2 Diabetes and Overweight or Obesity

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Obesity
    • Overweight
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Austria Germany Hungary Ireland Poland

  • Study of AMG 732 injection compared to placebo in patients with moderate to severe thyroid eye disease

    Not recruiting

    2 1
    Investigated Drugs:
    • AMG 732
    France Germany Greece Italy Poland Spain

  • Long-term study of dabrafenib and trametinib in children and adolescents with cancers that have V600 mutation

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Dabrafenib Mesylate
    • Trametinib
    • Trametinib Dimethyl Sulfoxide
    Belgium Czechia Denmark Finland France Germany +4

  • Study of cagrilintide and semaglutide combination versus placebo in people with type 2 diabetes and painful diabetic peripheral neuropathy

    Not recruiting

    2 1
    Investigated Diseases:
    • Diabetic neuropathy
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Denmark France Norway Spain

  • Study of BMN 351 given by intravenous infusion to evaluate safety and tolerability in patients with Duchenne Muscular Dystrophy

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Italy The Netherlands Spain

  • Study of luxdegalutamide and abiraterone combination in adult men with metastatic hormone-sensitive prostate cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • LUXDEGALUTAMIDE
    • Relugolix
    • Abiraterone
    Czechia France Germany Italy The Netherlands Poland +1
Previous Page
1 … 1,632 1,633 1,634 1,635 1,636 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!